Filing Details

Accession Number:
0000890465-13-000039
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-12-30 17:30:57
Reporting Period:
2013-12-26
Filing Date:
2013-12-30
Accepted Time:
2013-12-30 17:30:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
890465 Nps Pharmaceuticals Inc NPSP Biological Products, (No Disgnostic Substances) (2836) 870439579
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1192128 M Luke Beshar 550 Hills Drive
Bedminster NJ 07921
Evp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-12-26 29,250 $5.71 88,430 No 4 M Direct
Common Stock Acquisiton 2013-12-26 8,624 $3.34 97,054 No 4 M Direct
Common Stock Disposition 2013-12-26 37,874 $30.02 59,180 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options Disposition 2013-12-26 29,250 $0.00 29,250 $5.71
Common Stock Stock Options Disposition 2013-12-26 8,624 $0.00 8,624 $3.34
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-01-20 No 4 M Direct
106,376 2020-02-09 No 4 M Direct
Footnotes
  1. The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective December 12, 2013.
  2. The price shown above represents the weighted average price of the shares sold. The range of sales prices was $30.00 and $30.04. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
  3. On January 20, 2009, the Reporting Person received a grant of 73,125 performance-based stock options under the Issuer's 1998 Stock Option Plan. Options vest and become exercisable 50% on the second anniversary of the date of grant and 50% on the third anniversary of the grant date. The actual number of options that were determined based on performance of the Issuer's common stock relative to the performance of stock comprising a selected market index was 29,250. As of December 26, 2013 all 29,250 stock options have vested.
  4. On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of December 26, 2013, the performance criteria and the time-based criteria for 64,687 of these options has been satisfied. The options become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.